U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood Cancer

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news